Research & Education
CURE Expert Connections
To start your customized experience click the start button
Cancer of Unknown Primary
Diet and Exercise
Gastrointestinal stromal tumor
General Financial Topics
General Psychosocial Aspect Topics
Head & Neck Cancer
MDS and MPN
Side Effect Management
Advocacy & Research
Share Your Story
Newsletter Sign Up
Ovarian Cancer Heroes
Terms & Conditions
Cure Media Group, LLC.
2 Clarke Drive
Cranbury, NJ 08512
Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Using Vaccines to Bolster Immunotherapy Responses in Kidney Cancer
Vaccines are currently being tested in their potential to improve immunotherapy responses for patients with renal cell carcinoma.
Immunotherapy Data is Encouraging in Kidney Cancer
Elizabeth Plimack, M.D., discusses an update on the CheckMate-025 trial, comparing Opdivo to Afinitor in patients with metastatic renal cell carcinoma.
Combination Therapy Is Promising for Kidney Cancer, Expert Says
David F. McDermott, M.D., is optimistic about combination regimens shaping the treatment landscape for renal cell carcinoma.
Changing the Frontline Treatment of Kidney Cancer
After the approvals of agents in the second-line setting, researchers are now turning to improving the frontline treatment of kidney cancer.
New Agents Are Shifting Kidney Cancer Treatment Strategies
Will the newly approved kidney cancer treatments eventually end up in the frontline setting? Expert Chung-Han (Joe) Lee, M.D., weighs in.
Size Matters: Examining Obesity's Role in Cancer Outcomes
Obesity can negatively affect cancer treatment outcomes, trigger disease recurrence and shorten longevity. Organized weight loss programs and exercise can help patients protect themselves.
Expert Discusses Immunotherapy Combos in Kidney Cancer
Immunotherapy combinations are on the horizon for the treatment of renal cell carcinoma, Robert J. Motzer, M.D., says.
What's Next in Immunotherapy?
Christian M. Capitini, M.D.
Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.
Experts Discuss Immunotherapy's Role in the Shifting Landscape in Solid Tumors
A panel of experts recently discussed the evolving field of immunotherapy for solid tumor types.
TKIs Will Continue to Shape Kidney Cancer Treatment
TKIs will continue to shape the landscape of kidney cancer treatment, Robert A. Figlin, M.D., F.A.C.P., says.
Not a member?
Sign up now!
Continue without login
OPTIONAL INFORMATION: The following information helps us tailor CURE to fit your needs
Please type below what best describes your interests and click on the selection(s):
What is your status?
Out of Treatment